Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Cyclophosphamide 178Cytarabine 110fludarabine phosphate 102Methotrexate 98Busulfan 90Filgrastim 80Rituximab 72Peripheral Blood Stem Cell Transplantation 69Cyclosporine 60Radiotherapy 57Etoposide 57Mycophenolic Acid 56Antilymphocyte Serum 56fludarabine 55Tacrolimus 55Vincristine 47Whole-Body Irradiation 44Melphalan 42Dexamethasone 39Granulocyte Colony-Stimulating Factor 38sargramostim 34Methylprednisolone 34Alemtuzumab 34Daunorubicin 33Imatinib Mesylate 32Mercaptopurine 29Prednisone 27Idarubicin 26Doxorubicin 25Leucovorin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia × Silymarin × Clear all
NCT00055718 2013-12-18

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡